Amur Minerals (GB:CRTX) has released an update.
CRISM Therapeutics has inked a £230,000 service agreement to develop a novel hormone delivery implant with imphatec Limited, a move aligning with its revenue-generation and drug formulation strategies. The contract involves creating a customisable-dose implant for hormone deficiencies, with significant payments structured throughout the development milestones. This partnership may lead to further collaboration opportunities and comes as CRISM prepares a clinical trial application for its ChemoSeed product targeting high grade glioma.
For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.
